DUBLIN--(BUSINESS WIRE)--Aug 22, 2018--The "Degenerative Disc Disease - Pipeline Insights" drug pipelines has been added to ResearchAndMarkets.com's offering.

Degenerative Disc Disease - Pipeline Insights provides comprehensive insights about pipeline drugs across this indication. This report further provides information on the therapeutic development of more than 10+ pipeline drugs at various stages covering Phase II, Phase I, Pre-clinical and Discovery therapeutics and contains a comparative assessment by monotherapy, route of administration and molecule type. The report further features the dormant products for this indication. Leading companies in this space are Bone Therapeutics, Yuhan Corporation, BioRestorative Therapies and AnGes,.

Comparative analysis of pipeline drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.

Companies Mentioned

Bone Therapeutics BioRestorative Therapies TETEC Yuhan Corporation AnGes BiologicsMD DiscGenics Biopharm TissueGene

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kb8l6z/degenerative_disc?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180822005606/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/22/2018 02:31 PM/DISC: 08/22/2018 02:31 PM

http://www.businesswire.com/news/home/20180822005606/en